Trinity Biotech Statistics
Share Statistics
Trinity Biotech has 11.81M shares outstanding. The number of shares has increased by -70.24% in one year.
| Shares Outstanding | 11.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 48.8% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 10.96M |
| Failed to Deliver (FTD) Shares | 5.99K |
| FTD / Avg. Volume | 3.13% |
Short Selling Information
The latest short interest is 94.13K, so 0.78% of the outstanding shares have been sold short.
| Short Interest | 94.13K |
| Short % of Shares Out | 0.78% |
| Short % of Float | 0.81% |
| Short Ratio (days to cover) | 0.43 |
Valuation Ratios
The PE ratio is -0.69 and the forward PE ratio is -1.5.
| PE Ratio | -0.69 |
| Forward PE | -1.5 |
| PS Ratio | 0.29 |
| Forward PS | 0.1 |
| PB Ratio | -0.69 |
| P/FCF Ratio | -1.15 |
| PEG Ratio | n/a |
Enterprise Valuation
Trinity Biotech has an Enterprise Value (EV) of 80.19M.
| EV / Earnings | -3.34 |
| EV / Sales | 1.41 |
| EV / EBITDA | -3.33 |
| EV / EBIT | -2.97 |
| EV / FCF | -5.62 |
Financial Position
The company has a current ratio of 2.6, with a Debt / Equity ratio of -2.29.
| Current Ratio | 2.6 |
| Quick Ratio | 1.27 |
| Debt / Equity | -2.29 |
| Total Debt / Capitalization | 177.47 |
| Cash Flow / Debt | -0.21 |
| Interest Coverage | -2.67 |
Financial Efficiency
Return on equity (ROE) is 1% and return on capital (ROIC) is -62.1%.
| Return on Equity (ROE) | 1% |
| Return on Assets (ROA) | -0.4% |
| Return on Capital (ROIC) | -62.1% |
| Revenue Per Employee | 149.56K |
| Profits Per Employee | -63.21K |
| Employee Count | 380 |
| Asset Turnover | 0.96 |
| Inventory Turnover | 1.88 |
Taxes
| Income Tax | -59.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -63.6% in the last 52 weeks. The beta is 1.13, so Trinity Biotech's price volatility has been higher than the market average.
| Beta | 1.13 |
| 52-Week Price Change | -63.6% |
| 50-Day Moving Average | 1.46 |
| 200-Day Moving Average | 1.93 |
| Relative Strength Index (RSI) | 29.69 |
| Average Volume (20 Days) | 191.15K |
Income Statement
In the last 12 months, Trinity Biotech had revenue of $56.83M and earned -$24.02M in profits. Earnings per share was $-3.14.
| Revenue | 56.83M |
| Gross Profit | 19.45M |
| Operating Income | -27.05M |
| Net Income | -24.02M |
| EBITDA | -24.10M |
| EBIT | -27.05M |
| Earnings Per Share (EPS) | -3.14 |
Balance Sheet
The company has $3.69M in cash and $67.43M in debt, giving a net cash position of -$63.74M.
| Cash & Cash Equivalents | 3.69M |
| Total Debt | 67.43M |
| Net Cash | -63.74M |
| Retained Earnings | -48.64M |
| Total Assets | 97.45M |
| Working Capital | 18.02M |
Cash Flow
In the last 12 months, operating cash flow was -$11.56M and capital expenditures -$803.00K, giving a free cash flow of -$14.26M.
| Operating Cash Flow | -11.56M |
| Capital Expenditures | -803.00K |
| Free Cash Flow | -14.26M |
| FCF Per Share | -1.86 |
Margins
Gross margin is 34.22%, with operating and profit margins of -47.59% and -42.26%.
| Gross Margin | 34.22% |
| Operating Margin | -47.59% |
| Pretax Margin | -64.98% |
| Profit Margin | -42.26% |
| EBITDA Margin | -42.4% |
| EBIT Margin | -47.59% |
| FCF Margin | -25.09% |
Dividends & Yields
TRIB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -345.05% |
| FCF Yield | -133.38% |
Analyst Forecast
Currently there are no analyst rating for TRIB.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Feb 23, 2024. It was a backward split with a ratio of 1:5.
| Last Split Date | Feb 23, 2024 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | -0.43 |
| Piotroski F-Score | 2 |